Business Context and Reporting Period
This Form 8-K was filed by Seneca Biopharma, Inc. (formerly Neuralstem, Inc.) on October 29, 2019, reporting events that occurred on October 28, 2019. The company is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market.
Key Financial Metrics
This filing is a current report regarding a corporate name change and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
- Corporate Name Change: Effective October 28, 2019, the company changed its name from Neuralstem, Inc. to Seneca Biopharma, Inc. pursuant to a Certificate of Amendment filed with the Delaware Secretary of State.
- Trading Symbol Change: Effective November 1, 2019, the company's common stock will cease trading under the ticker symbol "CUR" and commence trading under the new ticker symbol "SNCA."
- CUSIP Update: The company's common stock has been assigned a new CUSIP number: 81689B103.
- Shareholder Rights: The name change does not affect the rights of security holders, and outstanding stock certificates remain valid without the need for exchange.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management commentary on future performance, or discussion of risks and contingencies. The document is strictly administrative, focusing on the legal and operational details of the name and ticker symbol transition.
Investor Verification Checklist
- Verify the new ticker symbol "SNCA" and CUSIP "81689B103" in brokerage accounts effective November 1, 2019.
- Confirm that existing stock certificates for "Neuralstem, Inc." remain valid and do not require physical replacement.
- Review the attached press release (Exhibit 99.01) for strategic rationale behind the rebranding to Seneca Biopharma, Inc.
- Note that this filing does not provide updated financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.